Search

Displaying results 2471 - 2480 of 10000 in total
  1. Drug

    Benfluorex

    go.drugbank.com/drugs/DB09022
    ApprovedWithdrawn

    Benfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine. It was patented and manufactured by a French pharmaceutical company Servier.

    Categories: Drugs Used in Diabetes
  2. Drug

    Beractant

    go.drugbank.com/drugs/DB06761
    Approved

    It is suspended in 0.9% sodium chloride solution, and heat-sterilized. … Administration of lung surfactant remains the cornerstone of therapy in this condition that is currently the leading cause of death in preterm infants.

    Products: SURVANTA ® 4 ML, Alveofact 45 mg/ml Pulver und Lösungsmittel zur Herstellung einer Suspension zur endotracheopulmonalen Instillation
  3. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    [L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. … [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.

    Products: PAXOTİN 33,1 MG/ML DAMLA, 20 ML, PAROXETIN AL 20MG FILMTABL
  4. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    [A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood … [L42455] Luspatercept is novel in that it ameliorates anemia via action on late-stage erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and [epoetin

  5. Drug

    Rotigotine

    go.drugbank.com/drugs/DB05271
    ApprovedInvestigational

    In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany. It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. … It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.

  6. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion … Bisegliptin is a compound for the treatment of type 2 diabetes.

    Categories: DPP-IV Inhibitors
  7. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    Abametapir is a novel pediculicidal metalloproteinase inhibitor used to treat infestations of head lice. … [A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163]

  8. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    Daridorexant reduces overactive wakefulness: in the investigational trials, daridorexant reportedly improved sleep and daytime functioning in patients with insomnia. … It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities such as hypertension, diabetes, and depression.

  9. Drug

    Econazole

    go.drugbank.com/drugs/DB01127
    Approved

    It is used topically in dermatomycoses also orally and parenterally.

  10. Drug

    Tenecteplase

    go.drugbank.com/drugs/DB00031
    ApprovedInvestigational

    296-299 in the protease domain. … It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids